Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096187
Filing Date
2024-08-13
Accepted
2024-08-13 16:08:07
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20240630.htm   iXBRL 10-Q 2285267
2 EX-31.1 fate-ex31_1.htm EX-31.1 12147
3 EX-32.1 fate-ex32_1.htm EX-32.1 6687
  Complete submission text file 0000950170-24-096187.txt   10128297

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20240630.xsd EX-101.SCH 1275853
60 EXTRACTED XBRL INSTANCE DOCUMENT fate-20240630_htm.xml XML 2239095
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 241201445
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)